RPC01-3202: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
|Effective start/end date||2/1/18 → 12/31/21|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.